Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
Success! The link has been copied to your clipboard.
The federal government and the Centers for Medicare and Medicaid Services (CMS) has strongly endorsed the shift to home dialysis. New regulations, reimbursement policy and legislation are accelerating progress towards this goal.
Connected health technologies that integrate with home machines are significantly improving the patient experience.
Home dialysis machines have evolved to become much more patient-centric and easier to use, improving flexibility and patient freedom.
Healthcare officials have long sought to lower costs while improving the quality of care. Home dialysis has been identified as a way to achieve both of these goals.
Fresenius Medical Care North America (FMCNA) has pledged to significantly increase the percentage of home dialysis treatments over the next few years. The company is committed to leading the entire industry through new products, services, education and infrastructure so this goal can be realized.